BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 2066762)

  • 1. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
    Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
    J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer.
    Alberts DS; Green S; Hannigan EV; O'Toole R; Stock-Novack D; Anderson P; Surwit EA; Malvlya VK; Nahhas WA; Jolles CJ
    J Clin Oncol; 1992 May; 10(5):706-17. PubMed ID: 1569443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
    Sutton GP; Stehman FB; Einhorn LH; Roth LM; Blessing JA; Ehrlich CE
    J Clin Oncol; 1989 Feb; 7(2):223-9. PubMed ID: 2915238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group.
    Swenerton K; Jeffrey J; Stuart G; Roy M; Krepart G; Carmichael J; Drouin P; Stanimir R; O'Connell G; MacLean G
    J Clin Oncol; 1992 May; 10(5):718-26. PubMed ID: 1569444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic experience of the North-West Oncology Group (GONO) on ovarian carcinoma.
    Conte PF; Gadducci A; Fioretti P; Bruzzone M; Brunetti I; Ragni N
    Eur J Gynaecol Oncol; 1994; 15(4):313-9. PubMed ID: 7957341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The study of cyclic maintenance chemotherapy with cisplatin, adriamycin, and cyclophosphamide (cyclic PAC chemotherapy) in patients with advanced ovarian cancer].
    Kobayashi H; Hayata T; Terao T; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1936-42. PubMed ID: 2592816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized study comparing carboplatin/cyclophosphamide and cisplatin/cyclophosphamide as first-line treatment in patients with stage III/IV epithelial ovarian cancer and small volume disease. German Ovarian Cancer Study Group (GOCA).
    Meerpohl HG; Sauerbrei W; Kühnle H; Schumacher M; Pfleiderer A
    Gynecol Oncol; 1997 Jul; 66(1):75-84. PubMed ID: 9234925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin, carboplatin, and cyclophosphamide combination chemotherapy in advanced-stage ovarian carcinoma: an Eastern Cooperative Oncology Group pilot study.
    Grem J; O'Dwyer P; Elson P; Simon N; Trump D; Frontiera M; Falkson G; Vogl S
    J Clin Oncol; 1991 Oct; 9(10):1793-800. PubMed ID: 1919629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
    Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
    Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Intermittent administration of the combination chemotherapy with cis-platin, adriamycin and cyclophosphamide (cyclic-PAC chemotherapy) for the ovarian cancers].
    Inoue M; Nakanishi K; Nakazawa A; Ogawa H; Shimizu H; Saitoh J; Tanaka Y; Ueda G; Tanizawa O
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Apr; 42(4):347-52. PubMed ID: 2358719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin-based combination chemotherapy with or without doxorubicin in advanced epithelial ovarian cancer: 8-year update of a randomized multicentric clinical trial. The Gruppo Oncologico Nord Ovest (GONO).
    Gadducci A; Brunetti I; Bruzzone M; Carnino F; Chiara S; Conte PF; Fioretti P; Foglia G; Ragni N
    Eur J Gynaecol Oncol; 1992; 13(1 Suppl):36-9. PubMed ID: 1511712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
    Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
    Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.